# Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

> **NCT05906576** · PHASE4 · RECRUITING · sponsor: **Taizhou Mabtech Pharmaceutical Co.,Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT05906576
- **Lead sponsor:** Taizhou Mabtech Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2026-11
- **Final completion:** 2027-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05906576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05906576, "Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05906576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*